Myovant Sciences Ltd.
MYOVDelisted Mar 10, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001679082
Myovant Sciences Ltd. was delisted on Mar 10, 2023; its insiders filed their last Form 4 on Mar 10, 2023; 118 institutions reported holding it in 13F filings for Q4 2022, worth $1.12B in total; no superinvestor held it.
13F holders, Q2 2021
Institutional positions in Myovant Sciences Ltd. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 108
- +4 vs. Q1 2021
- Shares held
- 32.4M
- +2.06M (+6.8%) vs. Q1 2021
- Total value
- $736.6M
- +$113.3M (+18.2%) vs. Q1 2021
- New holders
- 23
- 40 more added
- Sold out
- 19
- 27 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MYOV on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $27 |
| Q1 2026 | 1 | $27 |
| Q4 2025 | 1 | $27 |
| Q3 2025 | 1 | $27 |
| Q2 2025 | 1 | $27 |
| Q1 2025 | 1 | $27 |
| Q4 2024 | 1 | $27 |
| Q3 2024 | 1 | $27 |
| Q2 2024 | 1 | $27 |
| Q1 2024 | 1 | $27 |
| Q4 2023 | 1 | $27 |
| Q3 2023 | 1 | $27 |
| Q2 2023 | 1 | $27 |
| Q1 2023 | 2 | $27 |
| Q4 2022 | 118 | $1.12B |
| Q3 2022 | 98 | $511.5M |
| Q2 2022 | 91 | $369.3M |
| Q1 2022 | 89 | $400.0M |
| Q4 2021 | 110 | $475.6M |
| Q3 2021 | 105 | $677.6M |
| Q2 2021 | 108 | $736.6M |
| Q1 2021 | 104 | $623.2M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Myovant Sciences Ltd.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 774,317 | $17.6M | 0.00% | +15,738+2.1% | Added |
| BlackRock Inc. | 1,058,313 | $24.1M | 0.00% | +102,961+10.8% | Added |
| Norges Bank | 1,260,670 | $28.7M | 0.01% | +22,015+1.8% | Added |
| PFM Health Sciences, LP | 1,912,188 | $43.5M | 1.40% | −142,740−6.9% | Reduced |
| State Street Corp | 2,294,817 | $52.3M | 0.00% | +2,109,302+1,137.0% | Added |
| Bellevue Group AG | 5,269,039 | $120.0M | 1.17% | +75,000+1.4% | Added |
| Janus Henderson Group PLC | 5,421,017 | $123.4M | 0.05% | +181,735+3.5% | Added |
| Wellington Management Group LLP | 6,522,074 | $148.5M | 0.02% | +867,325+15.3% | Added |
| Tri Locum Partners LP | 0 | $0 | 0.00% | −321,101−100.0% | Sold out |
| Opaleye Management Inc. | 0 | $0 | 0.00% | −249,800−100.0% | Sold out |
| California Public Employees Retirement System | 0 | $0 | 0.00% | −88,200−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −36,997−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −34,700−100.0% | Sold out |
| QS Investors, LLC | 0 | $0 | 0.00% | −28,000−100.0% | Sold out |
| Paloma Partners Management Co | 0 | $0 | 0.00% | −18,131−100.0% | Sold out |
| Federation des caisses Desjardins du Quebec | 0 | $0 | 0.00% | −14,078−100.0% | Sold out |
| Susquehanna Fundamental Investments, LLC | 0 | $0 | 0.00% | −12,100−100.0% | Sold out |
| Trilogy Capital Inc. | 0 | $0 | 0.00% | −10,979−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −10,255−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −3,567−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −2,048−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −1,400−100.0% | Sold out |
| Sowell Financial Services LLC | 0 | $0 | 0.00% | −1,349−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −1,170−100.0% | Sold out |
| Total Clarity Wealth Management, Inc. | 0 | $0 | 0.00% | −350−100.0% | Sold out |
| Institutional & Family Asset Management, LLC | 0 | $0 | 0.00% | −85−100.0% | Sold out |
| Harel Insurance Investments & Financial Services Ltd. | 0 | $0 | 0.00% | −4,000−100.0% | Sold out |